New Firecrest Patient Portal, part of ICONIK Informatics Hub,
designed to enhance patient engagement and support patient recruitment
and retention.

June 17, 2015 11:00 AM Eastern Daylight Time

DUBLIN--(BUSINESS WIRE)--ICON plc, (NASDAQ: ICLR)a global provider of drug development
solutions and services to the pharmaceutical, biotechnology and medical
device industries, today announced the launch of the Firecrest Patient
Portal. This portal enables patients to view clinical trial information
and is specifically designed to enhance the patients understanding of
treatment before consenting to participate at an investigator site.

The Patient Portal solution is a component of ICON’s new informatics hub
designed to enhance the engagement of patient populations in the
development process and is line with ICH
E6 guidance, which recommends patients receive ‘ample time’ to
review consent materials and ask follow-up questions.

“The opportunity for education about the trial, before a face-to-face
meeting with their doctor, helps patients make truly informed decisions
about participation,” said Frances Abeton, Vice President, Firecrest at
ICON plc. “Improved patient comprehension of a trial can reflect
positively in patients’ relationships with investigators and
subsequently lead to better recruitment and retention rates. As drug
developers begin adopting electronic
informed consent platforms improved regulatory-compliant education
will be crucial. The Firecrest Patient Portal is a centralised solution
for patients, investigators and study staff, making it easier for all
involved to interact and stay informed.” said Abeton.

Patients using the Firecrest Patient Portal can find active trials,
complete pre-screening questionnaires and select a convenient study
location. As the Patient Portal is integrated with ICON’s Firecrest
Investigator Portal, investigators can engage directly with patients
that have shown interest, schedule visits, and examine live analytics
about the materials reviewed by a patient. Patients can read
visit-by-visit guides and as the trial progresses, patients can return
to the portal to review updates or notifications specific to them. They
will also be able to register interest in future clinical trials that
will support patient access for upcoming trials.

The Firecrest Patient Portal can be customised in any language, adapted
to country specific requirements, and branded as required by sponsors.

ICON plc is a global provider of drug development solutions and services
to the pharmaceutical, biotechnology and medical device industries. The
company specialises in the strategic development, management and
analysis of programs that support clinical development - from compound
selection to Phase I-IV clinical studies. With headquarters in Dublin,
Ireland, ICON currently, operates from 81 locations in 38 countries and
has approximately 11,200 employees. Further information is available at www.iconplc.com.

This press release contains forward-looking statements. These
statements are based on management's current expectations and
information currently available, including current economic and industry
conditions. These statements are not guarantees of future performance or
actual results, and actual results, developments and business decisions
may differ from those stated in this press release. The forward-looking
statements are subject to future events, risks, uncertainties and other
factors that could cause actual results to differ materially from those
projected in the statements, including, but not limited to, the ability
to enter into new contracts, maintain client relationships, manage the
opening of new offices and offering of new services, the integration of
new business mergers and acquisitions, as well as economic and global
market conditions and other risks and uncertainties detailed from time
to time in SEC reports filed by ICON, all of which are difficult to
predict and some of which are beyond our control. For these reasons, you
should not place undue reliance on these forward-looking statements when
making investment decisions. The word "expected" and variations of such
words and similar expressions are intended to identify forward-looking
statements. Forward-looking statements are only as of the date they are
made and we do not undertake any obligation to update publicly any
forward-looking statement, either as a result of new information, future
events or otherwise. More information about the risks and uncertainties
relating to these forward-looking statements may be found in SEC reports
filed by ICON, including its Form 20-F, F-1, S-8 and F-3, which are
available on the SEC's website at http://www.sec.gov.